This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

BG Medicine Highlights Role Of Galectin-3 Testing In Combating Hospital Readmissions At The American College Of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

Stocks in this article: BGMD

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that company representatives and independent researchers will highlight the clinical utility of galectin-3 blood testing in assessing the prognosis of patients with chronic heart failure through an extensive series of data presentations and company-sponsored events at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo in San Francisco, California.

As part of BG Medicine's presence at the ACC meeting, the company will host an educational symposium chaired by Alan Maisel, MD, Professor of Medicine, UCSD, Director of Coronary Care Unit and Heart Failure Program at the San Diego VA Medical Center, focused on how galectin-3 testing can help hospitals reduce readmissions. Representatives from BG Medicine will also be sponsoring booth N5519 which showcases how galectin-3 can impact the treatment of patients with chronic heart failure through a series of real-life case studies.

Reducing unplanned readmissions for patients continues to be one of the most urgent and pressing issues facing US-based hospitals today, particularly since October 2012, when the federal Centers for Medicare & Medicaid Services (CMS) enacted new rules that impose significant financial penalties on hospitals with excessive 30-day hospital readmission rates. Because heart failure patients with elevated galectin-3 are two-to-three times more likely to be readmitted to the hospital within 30 days of discharge, we believe that identifying these high-risk patients through galectin-3 testing is an efficient, simple and cost-effective tool in a hospital's strategy to reduce unplanned 30-day readmissions, enabling hospitals to better direct their intervention strategies and resources to those who need them most. i, ii,iii

Clinicians and hospital administrators interested in learning more about the unique role of galectin-3 testing as a risk stratification tool in reducing 30-day hospital readmissions can register to attend the BG Medicine dinner symposium From Emergency Department to Discharge: The Role of Biomarkers in Preventing Readmissions at www.galectin-3.com . The program will feature scientific and economic data from nationally-recognized experts from the emergency department, laboratory and administrative settings.

"For patients presenting to the emergency department, the initial triage and diagnosis by a clinician can influence the entire course of their care," said W. Frank Peacock IV, MD, FACEP Professor, Associate Chair & Research Director, Baylor College of Medicine and a featured panelist in the symposium. "Having ready access to a patient's galectin-3 level early in the assessment process may help clinicians make more informed management decisions across the spectrum of heart failure patients. Not only does knowledge of a patient's elevated galectin-3 provide valuable information as to which patients are in greatest need of aggressive management and at the highest risk for readmission, a low galectin-3 also identifies the lowest risk patients who may be appropriate candidates for observation or possibly early discharge."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs